Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
300
comparison of the induction of clinical remission
(achievement of a CDAI <150) of adalimumab 40 mg and 80 mg vs. placebo at Week 4.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Gastroenterology Associates of the East Bay
Berkeley, California, United States
Long Beach Gastroenterology Assoc.
Long Beach, California, United States
Sharp Rees-Stealy Medical Group
San Diego, California, United States
Gastroenterology Assoc. of Fairfield Co.
Bridgeport, Connecticut, United States
Cleveland Clinic Florida
Weston, Florida, United States
Shafran Gastroenterology Center
Winter Park, Florida, United States
Atlanta Gastroenterology Assoc.
Atlanta, Georgia, United States
Southeastern Digestive & Liver Disease
Savannah, Georgia, United States
Northwest Gastroenterologists, S.C.
Arlington Heights, Illinois, United States
University of Chicago
Chicago, Illinois, United States
...and 33 more locations